Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Sunitinib × Clear all

Phase

Phase 2 10 Phase 1 3 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 20 Gastrointestinal Stromal Tumors 9 Kidney Neoplasms 6 Breast Neoplasms 4 Neoplasms 3 Neoplasm Metastasis 3 Kidney Diseases 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urologic Neoplasms 1 Prostatic Neoplasms 1 Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1 Patient Preference 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Gastrointestinal Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Colorectal Neoplasms 1 Carcinoma, Islet Cell 1 Carcinoma, Hepatocellular 1 Carcinoid Tumor 1 Advanced Renal Cancer 1 Adenoma, Islet Cell 1

Interventions

Radiotherapy 53 Prednisone 53 Docetaxel 51 Leuprolide 48 Goserelin 47 bicalutamide 45 enzalutamide 28 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27 Androgen Antagonists 26 Flutamide 24 Triptorelin Pamoate 22 apalutamide 18 Gonadotropin-Releasing Hormone 17 Abiraterone Acetate 17 Radiation 15 abiraterone 14 Zoledronic Acid 14 Magnetic Resonance Spectroscopy 13 gallium 68 PSMA-11 12 Prednisolone 11 luprolide acetate gel depot 10 darolutamide 9 cabazitaxel 8 Standard of Care 8 Specimen Handling 8 Radiosurgery 8 Estramustine 8 Dexamethasone 8 Buserelin 8 Radiotherapy, Intensity-Modulated 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00676650 2013-03-08

SUN 1120

Pfizer

Phase 3 Terminated

873 enrolled 10 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡